BioRestorative Therapies, Inc.
BRTX
$1.09
$0.010.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.70% | 247.62% | 161.54% | 175.03% | 189.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.70% | 247.62% | 161.54% | 175.03% | 189.55% |
| Cost of Revenue | 3.24% | 409.23% | -- | -- | -- |
| Gross Profit | 1.59% | 241.35% | 140.87% | 155.83% | 170.58% |
| SG&A Expenses | -9.56% | -23.66% | -35.63% | -44.37% | -44.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.52% | 4.72% | -7.71% | -22.19% | -25.87% |
| Operating Income | -20.07% | -1.45% | 9.58% | 24.08% | 27.55% |
| Income Before Tax | -31.34% | -183.12% | -121.20% | 13.81% | -34.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.34% | -183.12% | -121.20% | 13.81% | -34.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.34% | -183.12% | -121.20% | 13.81% | -34.20% |
| EBIT | -20.07% | -1.45% | 9.58% | 24.08% | 27.55% |
| EBITDA | -20.16% | -1.25% | 9.91% | 24.50% | 27.97% |
| EPS Basic | -1.54% | -360.63% | -17.60% | 59.07% | 30.80% |
| Normalized Basic EPS | 12.95% | -284.67% | -0.74% | 66.48% | 30.80% |
| EPS Diluted | -1.58% | -355.59% | -17.26% | 59.11% | 30.93% |
| Normalized Diluted EPS | 12.95% | -284.67% | -0.74% | 66.48% | 30.80% |
| Average Basic Shares Outstanding | 24.41% | 38.64% | 65.15% | 84.08% | 74.29% |
| Average Diluted Shares Outstanding | 24.41% | 38.64% | 65.15% | 84.08% | 74.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |